• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Quest Diagnostics Incorporated

    4/4/25 4:39:42 PM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email
    DEFA14A 1 c111937_defa14a.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant [X]
    Filed by a Party other than the Registrant [_]

    Check the appropriate box:

     

    [_] Preliminary Proxy Statement
    [_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2))
    [_] Definitive Proxy Statement
    [X] Definitive Additional Materials
    [_] Soliciting Material Pursuant to Section 240.14a-12

     

    Quest Diagnostics Incorporated

     
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    [X]  No fee required
    [_]  Fee paid previously with preliminary materials
    [_]  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
     

     

     

     

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE QUEST DIAGNOSTICS INCORPORATED ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2025

     

    Notice of Annual Meeting of Stockholders

     

    WHEN AND WHERE IS THE STOCKHOLDERS MEETING?

     

    The 2025 Annual Meeting of Stockholders of Quest Diagnostics Incorporated (the “Company”) will be held at One Insights Drive, Clifton, New Jersey, on Thursday, May 15, 2025, at 10:30 a.m. local time. If you need directions to the Annual Meeting, please call 1-973-520-2900.

     

    WHAT IS BEING VOTED ON AT THE STOCKHOLDERS MEETING?

     

      • the election of ten director nominees named in the proxy statement;
      • an advisory resolution to approve the executive officer compensation disclosed in the Company’s 2025 proxy statement;
      • ratification of the appointment of our independent registered public accounting firm for 2025;
      • a stockholder proposal, as described in the accompanying proxy statement, if properly presented at the Annual Meeting; and
      • such other business as may properly come before the meeting or any adjournment or postponement thereof.

     

    WHAT DOES THE BOARD OF DIRECTORS RECOMMEND?

     

    The Quest Diagnostics Board of Directors recommends you vote FOR the election of the ten directors, FOR the advisory resolution to approve the executive officer compensation disclosed in the Company’s 2025 proxy statement, FOR ratification of the appointment of our independent registered public accounting firm for 2025 and AGAINST the stockholder proposal, as described in the accompanying proxy statement, if properly presented at the Annual Meeting.

     

    HOW CAN I GET A COMPLETE SET OF PROXY MATERIALS?

     

    This is not a proxy card. If you wish to submit your proxy on a traditional proxy card, you must request a paper copy of the proxy materials by following the instructions below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    The following documents are available at: www.ViewMaterial.com/DGX

     

      • 2025 Proxy Statement
      • 2024 Annual Report

     

    If you want to receive a paper or e-mail copy of these documents, you must request one; otherwise you will not receive a paper or e-mail copy. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 1, 2025, to facilitate timely delivery.

     

    You may request a paper or e-mail copy of the proxy materials by following the instructions below. You will be asked to provide the 11-digit control number (located by the arrow in the box below).

     

      1. Call the toll-free telephone number 1-800-516-1564 and follow the instructions provided, or
      2. Access the website, www.SendMaterial.com and follow the instructions provided, or
      3. Send an e-mail to [email protected] with your control number in the Subject line. Unless you instruct otherwise, we will reply to your e-mail with links to the proxy materials in PDF format for this meeting only.

     

     

    To vote your Quest Diagnostics Incorporated shares, you can attend the Annual Meeting of Stockholders and vote during the meeting or you can:

     

    1. Go to www.ViewMaterial.com/DGX
    2. Click on the icon to submit a proxy for your shares.
    3. Enter the 11 digit control number (located by the arrow in the box above).
    4. Follow the simple instructions to record your voting instructions.

    You are able to submit a proxy online until 11:59 p.m. (EDT) on May 14, 2025.

     
    Get the next $DGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    More analyst ratings

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

      In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.

      4/9/25 7:53:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

      Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J., April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening acce

      4/2/25 7:06:00 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Quest Diagnostics Incorporated

      10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      4/23/25 4:21:36 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      4/22/25 6:44:59 AM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Quest Diagnostics Incorporated

      DEFA14A - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      4/11/25 4:25:46 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/13/24 5:12:21 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      1/25/24 12:16:40 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/7/23 1:25:52 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Financials

    Live finance-specific insights

    See more
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

      SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

      4/1/25 4:23:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share

      Fourth quarter revenues of $2.62 billion, up 14.5% from 2023Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023Full year revenues of $9.87 billion, up 6.7% from 2023Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, announced today financial results for the fourth q

      1/30/25 6:45:00 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

      Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

      4/2/25 8:51:11 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics downgraded by Citigroup with a new price target

      Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

      3/4/25 7:20:57 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

      1/6/25 7:49:06 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President & CFO Samad Sam increased direct ownership by 0.28% to 26,451 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/2/25 4:33:33 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.26% to 10,612 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/2/25 4:32:51 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.39% to 21,087 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/2/25 4:32:07 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

      Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

      1/17/24 8:58:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

      SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

      3/3/23 4:30:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quotient Limited Announces Appointment of Chief Financial Officer

      JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

      10/12/21 8:45:00 AM ET
      $DGX
      $QTNT
      Medical Specialities
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances